semaglutide and cardiovascular outcomes in obesity without diabetes journal club Cardiovascular benefits of semaglutide: a
Description
The drug is only approved for use in adults with type 2 diabetes
Endocrine journal, 66(1), 51-63 Koo, H
Additional costs may apply
This provides biological plausibility for some observed effects, though mechanisms remain an area of ongoing investigation
Supported by: National University Health System Health Promotion and Health Services Research Seed Grant Disclosure: K
Dulcolax Pico Liquid (Sodium Picosulfate)
